5719-34-6

Usage

Uses

Used in Pharmaceutical Industry:
5,7-Dihydrothieno[3,4-d]pyrimidine-2,4-diol is used as a research compound for its potential pharmaceutical properties. Its unique structure allows it to be studied for various applications, such as an inhibitor of protein kinase C, which plays a crucial role in cellular signaling and is implicated in various diseases.
Used in Cancer Research:
In cancer research, 5,7-Dihydrothieno[3,4-d]pyrimidine-2,4-diol is used as a potential anti-cancer agent. Its ability to target specific cellular pathways and mechanisms involved in cancer development and progression makes it a valuable compound for the development of new therapeutic strategies against various types of cancer.
Used in Diabetes Treatment Research:
5,7-Dihydrothieno[3,4-d]pyrimidine-2,4-diol is also being investigated for its potential role in the treatment of diabetes. Its unique chemical structure and properties may offer new insights into the development of drugs that can help manage and treat this chronic condition.
Used in Neurological Disorders Research:
Furthermore, 5,7-Dihydrothieno[3,4-d]pyrimidine-2,4-diol is being explored for its potential applications in the treatment of neurological disorders. Its ability to interact with specific cellular targets and pathways may provide new avenues for the development of therapies to address a range of neurological conditions.
Overall, 5,7-Dihydrothieno[3,4-d]pyrimidine-2,4-diol is a versatile compound with a wide range of potential applications in the medical and pharmaceutical fields. Its ongoing research and development hold promise for the future of medicine, particularly in the areas of cancer, diabetes, and neurological disorders.

Upstream product

• 78647-31-1 Methyl tetrahydro-4-oxo-3-thiophenecarboxylate 
• 7400-45-5 dimethyl-3-thiaadipate 
• 2689-68-1 methyl 4-oxotetrahydrothiophene-3-carboxylate 
• 5719-20-0 5H,7H-2-ethylthiodihydrothieno<3,4-d>pyrimidin-4-one 

Downstream Products

• 74901-71-6 2,4-dichloro-5,7-dihydrothieno[3,4-d]pyrimidine 
• 1429638-92-5 (S)-1-cyclopropyl-3-(4-(4-(3-methylmorpholino)-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)phenyl)urea 
• 1429638-93-6 (S)-1-cyclopropyl-3-(4-(4-(3-methylmorpholino)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)phenyl)urea 
• 1054664-68-4 C₃₂H₂₆N₂O₉S 

Relevant academic research and scientific papers

MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS

The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments

MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH

The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.

1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and selective iGluR5 modulators

(S)-CPW399 ((S)-1) is a potent and excitotoxic AMPA receptor partial agonist. Modifying the cyclopentane ring of (S)-1, we developed two of the most potent and selective functional antagonists (5 and 7) for kainate receptor (KA-R) subunit iGluR5. Derivatives 5 and 7, with their unique pharmacological profile, may lead to a better understanding of the different roles and modes of action of iGluR1-5 subunits, paving the way for the synthesis of new potent, subunit selective iGluR5 modulators.

COMPOUNDS ACTIVE ON GLUTAMATERGIC RECEPTORS

The present invention relates to a compound of Formula (I) process for its preparation and uses thereof.

Synthesis of Cyclic and Acyclic Nucleoside Analogues Having a Thiophene or Dihydrothiophene Ring Fused to the d Side of an Uracil

Synthesis of cyclic and acyclic nucleosides was achieved by alkylation of various new aglycones following the Vorbrueggen and Niedballa's procedure .The analytical results allowed us to conclude that the alkylation ocurred on N1 site led to the β anomeric form for the cyclic nucleosides.